This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Musculoskeletal Conditions
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search
  • X (formerly Twitter) (opens in a new tab)
  • Bluesky (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:25642/feed
ISSN 2327-2236
Neurological Disorders
Vol. 1, Issue 1, 2013May 24, 2013 EDT

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication

Christian Frois, Thomas O’Connell, Jacqueline Pesa, John Fastenau,
prior authorizationaccessformularypreferred drug list (pdl)medicaidschizophreniaantipsychotic
Copyright Logoccby-4.0 • https://doi.org/10.36469/9853
Photo by freestocks.org on Unsplash
JHEOR
1.
Frois C, O’Connell T, Pesa J, Fastenau J. The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication. JHEOR. 2013;1(1):54-61. doi:10.36469/​9853

View more stats

Powered by Scholastica, the modern academic journal management system